The pharmaceutical industry is no stranger to fierce competition and patent disputes. In recent years, one drug has taken the market by storm and achieved blockbuster status. Ozempic, a medication for the treatment of type 2 diabetes, has garnered significant attention and popularity. However, its manufacturer, Novo Nordisk, finds itself in a battle to protect… Continue reading The Maker of Ozempic Is Trying to Block Compounded Versions of Its Blockbuster Drug